916902-55-1

Basic information

• Product Name: 6-Hydroxymethyl-1H-indazole
• Synonyms: 6-Hydroxymethyl-1H-indazole;1H-INDAZOLE-6-METHANOL;(1H-indazol-6-yl)methanol;(1H-pyrazolo[3,4-b]pyridin-6-yl)methanol;(1H-Indazol-6-yl)
• CAS NO: 916902-55-1
• Molecular Formula: C₈H₈N₂O
• Molecular Weight: 148.164
• Product Categories: Building Blocks;Indazole
• Mol File: 916902-55-1.mol
• Article Data: 7

Chemical Properties

• Melting Point: 159 °C
• Boiling Point: 380.3 °C at 760 mmHg
• Flash Point: 183.8 °C
• Appearance: /
• Density: 1.36 g/cm³
• Vapor Pressure: 1.84E-06mmHg at 25°C
• Refractive Index: 1.721
• Storage Temp.: 2-8°C
• PKA: 13.92±0.40(Predicted)
• CAS DataBase Reference: 6-Hydroxymethyl-1H-indazole(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Hydroxymethyl-1H-indazole(916902-55-1)
• EPA Substance Registry System: 6-Hydroxymethyl-1H-indazole(916902-55-1)

Safety Data

• Hazardous Substances Data: 916902-55-1(Hazardous Substances Data)

Usage

General Description

6-Hydroxymethyl-1H-indazole, also known as Indazol-6-yl-methanol, is a chemical compound with the molecular formula C8H8N2O. It is an indole derivative with a hydroxymethyl group attached to the 6-position of the indazole ring. 6-Hydroxymethyl-1H-indazole has been studied for its potential applications in organic synthesis and medicinal chemistry, as well as its role as a building block for the synthesis of various pharmaceutical compounds. It is a white crystalline powder with a molecular weight of 148.16 g/mol and has a melting point of 154-156°C. The chemical properties and applications of 6-Hydroxymethyl-1H-indazole make it a valuable compound in the field of pharmaceutical and organic chemistry.

InChI:InChI=1/C8H8N2O/c11-5-6-1-2-7-4-9-10-8(7)3-6/h1-4,11H,5H2,(H,9,10)

Upstream product

• 724-43-6 ethyl 1-acetyl-1H-indazole-6-carboxylate 
• 704-91-6 1H-indazole-6-carboxylic acid 
• 170487-40-8 1H-indazole-6-carboxylic acid methyl ester 
• 41191-92-8 3-amino-4-methylbenzoic acid ethyl ester 
• 2458-12-0 3-amino-p-toluic acid 
• 713-09-7 ethyl 1H-indazole-6-carboxylate 

Downstream Products

• 944904-42-1 3-iodo-1H-indazole-6-carbaldehyde 
• 152626-91-0 6-(bromomethyl)-1H-indazole 
• 669050-69-5 1H-indazole-6-carboxyaldehyde 

Relevant articles and documents

Expedient Synthesis of Thioether-Functionalized Hydrotris(indazolyl)borate as an Anchoring Platform for Rotary Molecular Machines

Major improvements in the synthesis of surface-mounted rotary molecular machines based on ruthenium(II) complexes are reported. The development of a one-pot indium(III)-mediated “N-deprotection/ester reductive sulfidation” sequence allowed step economy, reproducibility and high efficiency in the synthesis of the thioether-functionalized tripodal ligand. Switching to the thallium salt of hydrotris(indazolyl)borate and to microwave heating further optimized the preparation of the common intermediate in the modular synthesis of symmetric and dissymmetric molecular motors and gears. The penta(4-bromophenyl)cyclopentadienyl ruthenium(II) key precursor is now reproducibly synthesized in 5 steps and 31 % overall yield on the longest linear sequence. Subsequent fivefold Suzuki–Miyaura coupling with ferroceneboronic acid led to a new C5-symmetric pentaferrocenyl molecular motor.

GPR40 RECEPTOR AGONIST, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT

The present invention relates to a novel compound having GPR40 receptor agonist activity that promotes insulin secretion and inhibits blood sugar rise after glucose loading, and is thereby useful for the treatment of diabetes and complications thereof, the preparation method thereof and pharmaceutical composition containing them as an active ingredient.

Amine Compounds

There is provided a compound exhibiting an activity of suppressing immune response with reduced adverse drug reactions, which compound is useful in the chemotherapy for preventing or treating, for example, a wide range of various autoimmune diseases including systemic erythematodes, chronic rheumatoid arthritis, Type I diabetes, inflammatory bowel disease, biliary cirrhosis, uveitis, multiple sclerosis or other disorders, or chronic inflammatory diseases, or cancers, lymphoma or leukemia, or resistance to organ or tissue transplantation or rejection against transplantation. Novel amine compounds having an S1P1/Edg1 receptor agonist effect, possible stereoisomers or racemic bodies of the compounds, or pharmacologically acceptable salts, hydrates or solvates of the compound, the stereoisomers or the racemic bodies, or prodrugs of the compounds, the stereoisomers, the racemic bodies, the salts, the hydrates or the solvates, are provided.